Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 8, keine Gesamtzahl für „baseline“
Suchtreffer
Begriffe & Kennungen
Olazax · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) wa
Eintrag öffnenOlazax · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) wa
Eintrag öffnenOlazax · 4.8 · 13 Following short term treatment (median duration 22 days), weight gain ≥ 7% of baseline body weight (kg) was
Eintrag öffnenOlazax · 4.8 · 75 Following short term treatment (median duration 22 days), weight gain ≥ 7% of baseline body 13
Eintrag öffnenOlazax · 4.8 · During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥ 7 % from baseline
Eintrag öffnenOlazax · 4.8 · During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥ 7 % from baseline
Eintrag öffnenOlazax · 4.8 · During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥ 7 % from baseline
Eintrag öffnenOlazax · 4.8 · During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥ 7 % from baseline
Eintrag öffnenOlazax · 4.8 · During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥ 7 % from baseline
Eintrag öffnenOlazax · 4.8 · High Uric Acid 10 1 Clinically significant weight gain was observed across all baseline Body Mass Index (BMI)
Eintrag öffnenOlazax · 4.8 · weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common
Eintrag öffnenOlumiant · 4.8 · Neutropenia Mean neutrophil counts decreased at 4 weeks and remained stable at a lower value than baseline ove
Eintrag öffnenOlumiant · 4.8 · Neutropenia Mean neutrophil counts decreased at 4 weeks and remained stable at a lower value than baseline ove
Eintrag öffnenOpdivo · 4.5 · Systemic immunosuppression The use of systemic corticosteroids and other immunosuppressants at baseline, befor
Eintrag öffnenOpdivo · 4.5 · Systemic immunosuppression The use of systemic corticosteroids and other immunosuppressants at baseline, befor
Eintrag öffnenOpdivo · 4.8 · In the non-squamous NSCLC study (CA209057), the safety profile in patients with baseline renal or hepatic impa
Eintrag öffnenOpdivo · 4.8 · In the non-squamous NSCLC study (CA209057), the safety profile in patients with baseline renal or hepatic impa
Eintrag öffnenOrkambi · 4.8 · In patients treated with lumacaftor/ivacaftor (mean baseline 114 mmHg systolic and 69 mmHg diastolic), the max
Eintrag öffnenOrkambi · 4.8 · In patients treated with lumacaftor/ivacaftor (mean baseline 114 mmHg systolic and 69 mmHg diastolic), the max
Eintrag öffnenOzurdex · 4.8 · 28% of patients treated with OZURDEX had a ≥ 10 mm Hg IOP increase from baseline at one or more
Eintrag öffnen